Mitsubishi Pharma
Affiliate(s):
Aveo Pharmaceuticals (terminated 1/10)


Current as of: August 12, 2010  

Other Designation: MP-412, AV-412
Description: MP-412 is a novel compound of the anilinoquinazoline class that inhibits both epidermal growth factor receptor (EGFr), and HEr2 tyrosine kinase.  

Epidermal growth factor (EGF) receptor (EGFr, ErbB-1, ErbB1, HEr-1, HEr1) • HEr2/neu (HEr-2/neu, ErbB-2, c-erbB-2, ErbB2)  

Phase I (begin 10/06, terminated 7/10) USA, Argentina, Europe (Spain), phase I (begin 10/07, completed 7/10) USA - solid tumors, advanced, refractory or relapsed
 

Merck
Affiliate(s):
Xoma
Aveo Pharmaceuticals


Current as of: June 25, 2010  

Other Designation: AV-299, SCH900105
Description: AV-299 is a novel, potent, anti-hepatocyte growth factor/scatter factor (HGF/SF) humanized IgG1 monoclonal antibody (MAb).  

Hepatocyte growth factor/scatter factor (HGF/SF or SF/HGF)  

Phase I (begin 8/08, ongoing 6/10) USA - solid tumors, advanced, recurrent, metastatic or inoperable • lymphoma, advanced, recurrent, metastatic or inoperable
Phase I (begin 7/09, ongoing 3/10) USA - solid tumors, advanced, metastasized to the liver
Phase Ib/II (begin 12/09, ongoing 6/10) Singapore (combination) - solid tumors, advanced, refractory • non-small cell lung cancer, locally advanced, inoperable or metastatic, first or second line